12,372 trials
Osteoarthritis of the Knee
Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo — -3.12; -2.14 units on a…
Solid Tumors
Primary: Number of Participants With Adverse Events of Grades 3 and 4 Severity — 6; 2; 1; 0 Participants
Asthma
Primary: Percentage of Participants With Successful Self-administration of Their Observed Third Dose at Week 8 — 100 Percentage of participants
Chronic Kidney Disease · Depression
Primary: Change From Baseline to Exit in Depression Symptom Severity as Measured by the QIDS-C-16 Score. — -4.1; -4.2 units on a scale — p=0.82
Gout
Primary: Percentage of Participants With an sUA Level That is < 5.0 mg/dL — 82.5; 77.8 Percentage of participants
Severe Haemophilia A
Primary: Annualized Number of Bleeding Episodes (BE) in Phase II — 3.05 Annualized number of bleeding episodes — p=<0.05
Asthma
Primary: Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population — 188.77; 188.31 Litres per minute…
ST Elevation Myocardial Infarction (STEMI) · Coronary Artery Disease · Heart Failure
Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF
Pulmonary Arterial Hypertension
Primary: Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD) — 368.7; 380.3; 387.1; 399.9 meter — p=0.6120
Measles · Mumps · Rubella
Primary: Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2 — 98.0; 98.8; 99.5; 99.5 Percentage of…
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 — 14.8; 67.9; 57.5 percentage of participants — p=<0.0001
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 14; 13; 25; 28 participants
Rhinitis, Allergic, Perennial
Primary: Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing — 72; 39; 9; 77 Participants — p=0.003
Bacteriuria
Primary: Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC) — 26; 32; 21; 27 participants
Prostate Cancer
Primary: Time to Biochemical Failure Cumulative Incidence Percentile — 7.6; 6.8; 14.9; 12.4 Months — p=0.65